TriangleDISEASE & TREATMENT SETTING
Uterine Sarcoma
Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.
Exact scope
Uterine Sarcoma
- Source population
- Not part of this definition
- Disease extent
- Not part of this definition
- Treatment line
- Not part of this definition
- Stage
- Not part of this definition
- Resectability
- Not part of this definition
Biomarkers, prior therapy and derivation
- molecular
- prior therapy
- derivation status
- source-attested
- derivation note
- Derived from NCI topic(s): Uterine Sarcoma. Strongest NCIt resolution: exact. Entity-level scope; stage, biomarker and treatment line are not yet part of this definition.
- source wording
- Source null
5 more-specific settings
Study evidence for this setting
Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus
Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer
Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer
Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer
Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma
Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma
AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer
Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma
Temsirolimus in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies
Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Uterine Cancer
Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surger
Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
Gemcitabine Hydrochloride, Docetaxel, and Radiation Therapy in Treating Patients With Uterine Sarcoma That Has Been Removed By Surgery
Source relationships and population-mapping limitations
- bindings
- release id
- clinical-indications-draft-1
- disease state id
- ds-uterine-sarcoma
- binding id
- ncit-C6339
- source collection
- ncit-concept
- source key
- C6339
- source excerpt
- Source null
- match status
- exact
- match note
- Source null
- recorded at
- 2026-09-10T00:00:00Z
- mappings
Download this complete draft source relationship record →
Preserved source evidence · Not medical advice